Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.56 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL645929 | 0.95 | PTPN1 (0.58) | PTPN1PGAM1PTPN2PARP14BRD4 | |
| SCHEMBL12971498 | 0.92 | PTPN1 (0.60) | PTPN1PTPN2 | |
| SCHEMBL647629 | 0.87 | PTPN1 (0.64) | PTPN1PTPN2 | |
| SCHEMBL646413 | 0.87 | PTPN1 (0.56) | PTPN1PGAM1PTPN2PARP14 | |
| SCHEMBL646154 | 0.86 | PTPN1 (0.60) | PTPN1PTPN2 | |
| SCHEMBL648987 | 0.85 | PTPN1 (0.53) | PTPN1PTPN2BRD4 | |
| SCHEMBL649018 | 0.84 | PTPN1 (0.52) | PTPN1PTPN2BRD4MRGPRX1 | |
| SCHEMBL647122 | 0.84 | PTPN1 (0.57) | PTPN1PTPN2 | |
| SCHEMBL648664 | 0.84 | PTPN1 (0.55) | PTPN1PTPN2BRD4BRAF | |
| SCHEMBL646019 | 0.83 | PTPN1 (0.53) | PTPN1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963294-B1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2012-10-10 | — | — | EP | claimed |
| US-8119666-B2 | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | claimed |
| US-8119666-B2 | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |